

A Reliable Research Partner in Life Science and Medicine

Recombinant Mouse Ifnb1 Protein(His Tag)

Catalog Number: PDMM100220

Note: Centrifuge before opening to ensure complete recovery of vial contents.

Description

Species Mouse

Source HEK293 Cells-derived Mouse Ifnb1 protein Met1-Asn182, with an C-terminal His

 Calculated MW
 19.9 kDa

 Observed MW
 30-35 kDa

 Accession
 P01575

Bio-activity Not validated for activity

Properties

Purity > 85% as determined by reducing SDS-PAGE.

Endotoxin < 1.0 EU/mg of the protein as determined by the LAL method

Storage Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -

80°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of

reconstituted samples are stable at < -20°C for 3 months.


ShippingThis product is provided as lyophilized powder which is shipped with ice packs.FormulationLyophilized from a 0.2 μm filtered solution in PBS with 5% Trehalose and 5%

Mannitol.

Reconstitution It is recommended that sterile water be added to the vial to prepare a stock solution

of 0.5 mg/mL. Concentration is measured by UV-Vis.

Data



SDS-PAGE analysis of Mouse Ifnb1 proteins, 2µg/lane of Recombinant Mouse Ifnb1 proteins was resolved with SDS-PAGE under reducing conditions, showing bands at 30-35 kDa

Background

For Research Use Only

 Toll-free: 1-888-852-8623
 Tel: 1-832-243-6086
 Fax: 1-832-243-6017

 Web: www.elabscience.com
 Email: techsupport@elabscience.com

Elabscience®

Elabscience Bionovation Inc.

A Reliable Research Partner in Life Science and Medicine

Interferons (IFNs) are natural glycoproteins belonging to the cytokine superfamily and are produced by the cells of the immune system of most vertebrates in response to challenges by foreign agents such as viruses, parasites, and tumor cells. Interferon-beta (IFN beta) is an extracellular protein mediator of host defense and homeostasis. IFN beta has well-established direct antiviral, antiproliferative, and immunomodulatory properties. Recombinant IFN beta is approved for the treatment of relapsing-remitting multiple sclerosis. The recombinant IFN beta protein has the theoretical potential to either treat or causes autoimmune neuromuscular disorders by altering the complicated and delicate balances within the immune system networks. It is the most widely prescribed disease-modifying therapy for multiple sclerosis (MS). Large-scale clinical trials have established the clinical efficacy of IFN beta in reducing relapses and slowing disease progression in relapsing-remitting MS. IFN beta therapy was shown to be comparably beneficial for opticospinal MS (OSMS) and conventional MS in Japanese. IFN beta is effective in reducing relapses in secondary progressive MS and may have a modest effect in slowing disability progression. In addition to the common antiviral activity, IFN beta also induces increased production of the p53 gene product which promotes apoptosis and thus has a therapeutic effect against certain cancers. The role of IFN-beta in bone metabolism could warrant its systematic evaluation as a potential adjunct to therapeutic regimens of osteolytic diseases. Furthermore, IFN beta might play a beneficial role in the development of chronic progressive CNS inflammation.

For Research Use Only

 Toll-free: 1-888-852-8623
 Tel: 1-832-243-6086
 Fax: 1-832-243-6017

 Web: w w w .elabscience.com
 Email: techsupport@elabscience.com